CENTURY THERAPEUTICS INC (IPSC)
Health Care · Biotechnology · NASDAQ
Century Therapeutics is pioneering scalable, off-the-shelf allogeneic cell therapies using an iPSC-derived platform to treat autoimmune diseases and cancer.
What CENTURY THERAPEUTICS INC does
Century Therapeutics is a biotechnology company developing off-the-shelf, allogeneic cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. The company utilizes a proprietary platform based on induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, and its Allo-Evasion™ technology to create functional, scalable immune cell products that avoid host immune rejection.
Recent developments
Century completed a pre-IND meeting with the FDA for its lead program, CNTY-813, reaching alignment on nonclinical data and manufacturing strategy, with an IND submission on track for 4Q 2026. The company also confirmed its cash runway extends into 1Q 2029 following a 2026 private placement.
From CENTURY THERAPEUTICS INC's filing of 2026-08-12.
Themes: Cell therapy, Autoimmune diseases, Type 1 diabetes / T1D, Oncology, Gene editing, iPSC technology, Allogeneic cell therapy
Fundamentals
- Price$1.64 as of 2026-10-20 close
- Market cap$297M as of 2026-08-03 (share count; price 2026-10-20)
- 1-year return+187.2% 2025-10-20 close $0.571 → 2026-10-20 close $1.64
- P/En/a negative earnings
- Net margin-8.8% FY2025, SEC XBRL
- ROE-6.0% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+1556.8% FY2025, SEC XBRL
- Revenue CAGR (3y)+175.9% SEC XBRL
- Beta1.52 as of 2026-09-02
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How IPSC compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | — | -$37M | -$35M | -$0.17 | -$20M† | $694000† |
| Q1 FY2026 2026-03-31 | — | -$24M | -$22M | -$0.11 | -$25M | $584000 |
| Q4 FY2025 2025-12-31 | — | -$21M† | -$19M† | -$0.25† | -$16M† | -$139000† |
| Q3 FY2025 2025-09-30 | — | -$36M | -$34M | -$0.40 | -$26M† | $195000† |
| Q2 FY2025 2025-06-30 | — | -$35M | -$33M | -$0.38 | -$28M† | $317000† |
| Q1 FY2025 2025-03-31 | $109M | $74M | $77M | $0.89 | -$35M | $475000 |
| Q4 FY2024 2024-12-31 | $4M† | -$37M† | -$36M† | -$0.43† | -$24M† | — |
| Q3 FY2024 2024-09-30 | $791000 | -$35M | -$31M | -$0.37 | -$28M† | — |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$50M
- Short-term investments$70M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How CENTURY THERAPEUTICS INC looks technically
CENTURY THERAPEUTICS INC (IPSC) is trading 21.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 18 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 10 trading days ago. It is 46.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 21.3% below its 200-day average, the long-term trend line — a long-term downtrend | -21.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.82 | $1.82 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.08 | $2.08 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 2.08. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 18 trading days ago — a "death cross", a bearish long-term signal | 18 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with buyers in control | 26.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 51.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($1.22 to $1.75) — its "stochastic" reading is 80 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 80.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.04 | $3.04 |
|---|---|---|
| From the 52-week high | it is 46.1% below its 52-week high (its highest price of the past year) | -46.0% |
| Above the 52-week low | it is 277.0% above its 52-week low (its lowest price of the past year) | +277.0% |
| Below the 52-week high | it is 46.1% below its highest point of the past year | 46.0% |
| Since a 20-day breakout | it made a new 20-day low about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day low about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $11.95 (set on 2022-11-11) | $11.95 |
| Given back of the 52-week move | over the past year its closes ranged ($0.465 to $2.94), and it has given back around half of its rise from last year’s low — 53% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.33 to $1.41. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 52.5% |
| From the all-time high | it is 86.3% below its all-time high | -86.3% |
| Nearest price level | it is trading 11.0% below a resistance level at $1.82 — a price it turned at twice since 2024-12-02, most recently on 2026-01-21. Since 2024-10-21 it has 6 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +11.0% |
| All-time low | its lowest closing price on record is $0.3418 (set on 2025-04-09) | $0.3418 |
| Above the all-time low | it is 379.8% above its all-time low | +379.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 91% of the past ~6 months) | 91st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1458 between its high and its low — about 8.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1458 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.25 and $1.80 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.25 – $1.52 – $1.80 |
| Typical daily range (% of price) | its price moves about 8.9% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.9% |
| Stretch from the 200-day average | it is trading 3.0 daily ranges below its 200-day average price (21.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.98× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.4% |
|---|---|---|
| Gap filled | a 2.3% gap down opened on 2026-10-07 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 9 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +19.71% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 12.8 percentage points (the stock lost 11.8% while the market gained 1.0%) | -12.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 28.7 percentage points (the stock lost 25.1% while the market gained 3.6%) | -28.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 38.4 percentage points (the stock lost 29.9% while the market gained 8.5%) | -38.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 172.7 percentage points (the stock gained 187.2% while the market gained 14.6%) | +172.7% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, a strong uptrend, with buyers in control — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 20% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -19.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 22% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.11 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -22.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $1.71 — a volume-weighted average of daily closes over 49 sessions, not a true tick-by-tick VWAP. | -4.2% |
Price levels it has turned at before
IPSC last closed at $1.64 on 2026-10-20. Since 2024-10-21 it has turned at 6 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.82 | Resistance | 11.0% above the last close | turned there twice · 2024-12-02 to 2026-01-21 |
| $1.98 | Resistance | 20.4% above the last close | turned there twice · 2026-06-05 to 2026-08-31 |
| $2.09 | Resistance | 27.4% above the last close | turned there twice · 2026-05-19 to 2026-07-13 |
| $0.684 | Support | 58.3% below the last close | turned there twice · 2025-02-11 to 2025-07-28 |
| $0.6512 | Support | 60.3% below the last close | turned there three times · 2025-03-18 to 2025-11-04 |
| $0.6385 | Support | 61.1% below the last close | turned there twice · 2025-05-20 to 2025-07-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $2.08.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.49 and $1.79 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $1.22.
This reading has stood for 4 trading days, since 2026-10-15.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Recent death cross (50-day crossed below 200-day) · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$4.75 range $2.00 – $8.00; median $4.50
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IPSC
- Consensus EPS estimate-$0.11 next reporting period, as of 2026-10-16
- Estimate change, 30 days$0.00 from -$0.11, on 2026-09-11, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has incurred significant losses since inception, has never generated product revenue, and will require substantial additional funding to reach commercialization.","The company is in early-stage development, and its product candidates are subject to lengthy, expensive clinical trials and regulatory approval processes that may fail."]
What changed in the latest 10-Q
AI-assisted comparison of IPSC's 10-Q filed 2026-08-12 against the prior one filed 2026-05-13.
Risk Factors
- Added:
- Newer filing (filed 2026-08-12) adds a subsection under Item 5 titled "(c) Insider Trading Arrangements" disclosing that during the quarter ended June 30, 2026, none of the directors or officers adopted, modified, or terminated a Rule 10b5-1(c) trading arrangement.
- Removed:
- Older filing (filed 2026-05-13) included a Rule 10b5-1 trading plans table under Item 5 showing that Gregory Russotti, Chief Technology and Manufacturing Officer, terminated a Rule 10b5-1 trading arrangement effective February 10, 2026 (maximum 160,000 shares, scheduled expiration September 30, 2026) and adopted a Rule 10b5-1 trading arrangement effective February 18, 2026 (maximum 200,000 shares, scheduled expiration February 12, 2027).
- Older filing (filed 2026-05-13) included a footnote to the trading arrangements table stating that a trading arrangement may expire earlier if all contemplated transactions are completed, upon termination by the broker or holder, or as otherwise provided.
- Older filing (filed 2026-05-13) listed Exhibit 4.1 (Form of Pre-Funded Warrant, incorporated by reference to Exhibit 4.1 of Form 8-K filed January 8, 2026).
- Older filing (filed 2026-05-13) listed Exhibit 4.2 (Form of Common Warrant, incorporated by reference to Exhibit 4.2 of Form 8-K filed January 8, 2026).
- Older filing (filed 2026-05-13) listed Exhibit 10.1 (Securities Purchase Agreement, dated January 7, 2026, incorporated by reference to Exhibit 10.1 of Form 8-K filed January 8, 2026).
- Older filing (filed 2026-05-13) listed Exhibit 10.2 (Registration Rights Agreement, dated January 7, 2026, incorporated by reference to Exhibit 10.2 of Form 8-K filed January 8, 2026).
- Older filing (filed 2026-05-13) listed Exhibit 10.3 (First Amendment to the Catalent License Agreement, dated March 25, 2026, between the Company and Catalent).
- Reworded:
- Newer filing (filed 2026-08-12) lists Exhibit 3.1 (Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation, incorporated by reference to Exhibit 3.1 of Form 8-K filed June 12, 2026); no such Exhibit 3.1 appears in the older filing.
- Newer filing (filed 2026-08-12) lists Exhibit 10.1 (Exclusive License Agreement for MSK's Technology, dated August 24, 2023, among the Company and Memorial Sloan-Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases, and Sloan-Kettering Institute for Cancer Research); the older filing's Exhibit 10.1 was a different agreement.
- Newer filing (filed 2026-08-12) lists Exhibit 10.2 (Amended and Restated Employment Agreement with Chad Cowan, Ph.D., dated June 15, 2026); the older filing's Exhibit 10.2 was a different agreement.
- Newer filing (filed 2026-08-12) lists Exhibit 10.3 (Third Amendment to Lease, dated June 15, 2026, between uCity Square One Owner, LLC and Century Therapeutics, Inc.); the older filing's Exhibit 10.3 was a different agreement.
- Newer filing (filed 2026-08-12) states the cover page is for the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026; older filing states the quarter ended March 31, 2026.
- Newer filing (filed 2026-08-12) signature page is dated August 12, 2026; older filing signature page is dated May 13, 2026.
- Notes:
- The Risk Factors section text itself (the statement about no material changes in risk factors from the Form 10-K for the year ended December 31, 2025) is identical between the two filings.
- The provided excerpts include materials beyond the Risk Factors section (Items 2 through 6, exhibits, and signatures), so changes reported include differences in those surrounding sections within the supplied excerpts.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 5 sells ($10352) — 2 selling insiders
- Last 180 days · read to 2026-10-160 buys · 10 sells ($22061) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-14. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IPSC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IPSC as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 11,905,156
- Reported value $29,167,632
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IPSC's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IPSC had 29,218,775 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
IPSC had 16.1% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 50.91 days to cover at the same settlement.
- Reported short interest (shares) 29,218,775
- Short interest (% of shares outstanding) 16.1%
- Prior settlement (shares) 29,354,630
- Reported change -0.46%
- Days to cover (reported) 50.91
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Fate Therapeutics (FATE)
- Allogene Therapeutics (ALLO)
- Editas Medicine (EDIT)
- Crispr Therapeutics (CRSP)
- Beam Therapeutics (BEAM)
- Intellia Therapeutics (NTLA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IPSC vs…
CENTURY THERAPEUTICS INC is found in…
IPSC ranks in…
Frequently asked questions
What does CENTURY THERAPEUTICS INC (IPSC) do?
Century Therapeutics is a biotechnology company developing off-the-shelf, allogeneic cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. The company utilizes a proprietary platform based on induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, and its Allo-Evasion™ technology to create functional, scalable immune cell products that avoid host immune rejection.
What sector is CENTURY THERAPEUTICS INC (IPSC) in?
CENTURY THERAPEUTICS INC (IPSC) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are CENTURY THERAPEUTICS INC's (IPSC) competitors?
Notable peers of CENTURY THERAPEUTICS INC (IPSC) include Fate Therapeutics, Allogene Therapeutics, Editas Medicine, Crispr Therapeutics and Beam Therapeutics. This peer set is informational only — not financial advice.
Is CENTURY THERAPEUTICS INC (IPSC) overbought or oversold right now?
CENTURY THERAPEUTICS INC (IPSC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IPSC come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.